Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
- 1 September 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (17) , 7959-7967
- https://doi.org/10.1158/0008-5472.can-04-3541
Abstract
Prostate cancer is initially androgen dependent and there is evidence that androgen receptor continues to play a role in androgen-independent prostate cancer. Androgen receptor activity depends both on the level of androgens and on the level of coactivators that interact with androgen receptor. Our goal was to evaluate the role of the androgen receptor coactivator SRC-1 in prostate cancer progression. Using tissue arrays to measure SRC-1 protein levels, we found that increased SRC-1 expression in clinically localized, androgen-dependent cancer is associated with clinical and pathologic variables of increased tumor aggressiveness. Interestingly, there was variable expression of SRC-1 in normal prostate tissue which correlated with the staining intensity of the corresponding cancer tissue. To test the contribution of SRC-1, we examined its role in androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer cell lines. Using small interfering RNA to reduce expression of androgen receptor, we found that androgen receptor was required both for cell growth and for basal expression of prostate-specific antigen in the androgen-independent C4-2 cell line. Thus, although the cells can grow in an androgen-depleted medium, they remained androgen receptor dependent. Reduction of SRC-1 expression significantly reduced growth and altered androgen receptor target gene regulation in both LNCaP and C4-2 cell lines whereas it had no effect on the growth of the androgen receptor–negative PC-3 and DU145 prostate cancer cell lines. Although the requirement for androgens and androgen receptor in the development of prostate cancer is well established, our study implicates enhanced androgen receptor activity through elevated expression of SRC-1 in the development of more aggressive disease in men with prostate cancer.Keywords
This publication has 28 references indexed in Scilit:
- First‐And Second‐Generation Antisense Oligonucleotide Inhibitors Targeted Against Human C‐ raf KinasePublished by Wiley ,2007
- Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of MalignancyJournal of Clinical Oncology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1)Molecular Endocrinology, 1999
- Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functionsProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998.The Journal of Steroid Biochemistry and Molecular Biology, 1999
- Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor SuperfamilyScience, 1995
- Improvement in the efficiency of the in vitro transformation assay method using BALB/3T3 A31–1–1 cellsCarcinogenesis: Integrative Cancer Research, 1995
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995
- Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cellsInternational Journal of Cancer, 1994
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990